瑞普生物：报告期内通过优化产品结构和内部经营管理提升，原料药板块经营状况显著改善

Core Insights - The company reported significant improvement in the raw material drug sector, reducing losses by over 10 million yuan compared to the same period last year [1] Group 1: Key Initiatives - The company is implementing three key measures to enhance the performance of the raw material drug sector: 1. Deepening lean cost reduction by optimizing production processes and enhancing centralized procurement management to effectively lower unit production costs [1] 2. Accelerating overseas market expansion to continue increasing export share [1] 3. Optimizing product structure to increase the proportion of high-margin products, with plans to launch new products such as hydrochloride voriconazole dihydrate and cefotaxime crystals in the second half of the year to enrich the high value-added product matrix [1]